SCHEMBL857614

SCHEMBL857614

COC(=O)c1cc(I)c(OC)cc1N

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.74
CFTR P13569 3/20 0.60
GAA P10253 7/20 0.57
POLB P06746 2/20 0.54
ALDH1A1 P00352 6/20 0.49
HSD17B10 Q99714 6/20 0.49
MAPT P10636 3/20 0.49
HPGD P15428 2/20 0.49
GLA P06280 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
ATM Q13315 1/20 0.49
ABL1 P00519 1/20 0.47
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
NQO2 P16083 1/20 0.43
MAPK1 P28482 2/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17137165 0.93 KDM4E (0.74) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL2596444 0.86 GAA (0.66) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL372600 0.85 KDM4E (1.00) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL31408659 0.85 KDM4E (1.00) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL28443885 0.84 KDM4E (0.51) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL28435087 0.84 KDM4E (0.51) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL28922445 0.84 CFTR (0.66) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL23520824 0.81 KDM4E (0.77) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL1015430 0.81 KDM4E (0.77) KDM4ECFTRGAAPOLBALDH1A1
SCHEMBL17742903 0.81 KDM4E (0.47) KDM4ECFTRGAAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085058-A1 DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 YUAN YU (US) 2026-03-26 US disclosed
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. 2025-07-31 US disclosed
EP-4392423-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE Arthrosi Therapeutics, Inc. (US) 2024-07-03 EP disclosed
WO-2024035921-A1 DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2024-02-15 WO disclosed
EP-4148056-A1 SOS1 INHIBITOR CONTAINING PHOSPHORUS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-03-15 EP disclosed
WO-2023028054-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
WO-2022148442-A1 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-07-14 WO disclosed
WO-2022148442-A1 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-07-14 WO disclosed
CN-114716478-A 6-substituted phosphoryl quinazoline derivative and preparation method and application thereof 武汉人福创新药物研发中心有限公司 2022-07-08 CN disclosed
EP-3878850-A1 NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2021-09-15 EP disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2643317-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-10-02 EP disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2013025958-A1 AMINO QUINAZOLINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-02-21 WO disclosed
WO-2012071519-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
CN-102459249-A Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases EXELIXIS INC 2012-05-16 CN disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KDM4E 610/4885CFTR 3385/4885GAA 752/4885
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE EGFR, ABL1, ERBB2 KDM4E 3572/4885CFTR 255/4885GAA 1111/4885
US-20260085058-A1 DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 SOS1, KRAS, SOS2 KDM4E 924/4885CFTR 764/4885GAA 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.